Compare SPRU & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRU | GRML |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 29.2M |
| IPO Year | 2019 | 2022 |
| Metric | SPRU | GRML |
|---|---|---|
| Price | $1.33 | $5.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.2K | ★ 3.5M |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.30 | 31.25 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $23,194,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.50 | ★ N/A |
| Revenue Growth | ★ 48.68 | N/A |
| 52 Week Low | $1.29 | $0.16 |
| 52 Week High | $6.75 | $18.21 |
| Indicator | SPRU | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 29.89 | 47.17 |
| Support Level | N/A | $0.28 |
| Resistance Level | $2.46 | $7.53 |
| Average True Range (ATR) | 0.07 | 0.77 |
| MACD | -0.01 | -0.24 |
| Stochastic Oscillator | 11.54 | 34.81 |
Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.